Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that it ...

This article has been revised and clarified. Pasadena-based biopharma company Arrowhead Pharmaceuticals Inc. had a ...

It has been about a month since the last earnings report for Sarepta Therapeutics (SRPT). Shares have added about 26.4% in that time frame, outperforming the S&P 500. But investors have to be ...

A drug safety group has delivered a positive analysis for a Sarepta Therapeutics-licensed RNA medicine, with the same study also hitting an enrollment target, triggering a $200 milestone payment due ...

Shares of Sarepta Therapeutics Inc. plunged in extended trading Monday after the biotechnology company disclosed disappointing drug-trial data, which could lengthen the timeline of the regulatory ...

Records: Baton Rouge HomeSchool enters at 1-0; Sarepta is listed 0-0. Last meeting: No prior meeting on the ScoreBookLive record for these teams. Status: upcoming ...

Two Sarepta Therapeutics drugs for treating different genetic subsets of patients with Duchenne muscular dystrophy failed the confirmatory study required of their accelerated FDA approvals. Sarepta ...

Sarepta's Phase 3 ESSENCE study, which tested Amondys 45 and Vyondys 53 as treatments for Duchenne muscular dystrophy, failed to meet its primary endpoint of showing clear benefit over placebo. The ...

A long-running confirmatory trial of two of Sarepta Therapeutics’ Duchenne muscular dystrophy drugs has missed its main goal. The development comes just as the company and the FDA work to formally ...

Sarepta nevertheless plans to push for full FDA approval of Vyondys 53 and Amondys 45 based on what it said are “encouraging trends” in efficacy. The challenges just keep coming for Sarepta ...

Sarepta Therapeutics Inc. shares plunged after a trial designed to confirm the benefits of two of its older drugs failed to show clear patient improvement, raising questions about their future. The ...